Evidence map›Paper›PMID 35762322›Full record

Trial reportCirculation2022

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.

Gerasimos Filippatos, Javed Butler, Dimitrios Farmakis, Faiez Zannad, Anne Pernille Ofstad, João Pedro Ferreira, Jennifer B Green, Julio Rosenstock, Sven Schnaidt, Martina Brueckmann and 4 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03057951. Cited by 76 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 11 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03057951 phase3completed

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Ran2017Enrolled5,988Registered outcomes10Posted comparisons10ConditionsHeart FailureArmsempagliflozin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 11 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  18. Article
  19. Review
  20. Observational

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 13 countries.

Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (G.F.).ORCID 0000-0002-5640-0332
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX (J.B.).ORCID 0000-0001-7683-4720
Dimitrios FarmakisUniversity of Cyprus Medical School, Nicosia (D.F.).ORCID 0000-0001-8364-3447
Faiez ZannadCentre d'Investigations Cliniques Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France (F.Z., J.P.F.).ORCID 0000-0001-7456-1570
Anne Pernille OfstadMedical Department, Boehringer Ingelheim Norway KS, Asker (A.P.O.).ORCID 0000-0003-2714-0102
João Pedro FerreiraCentre d'Investigations Cliniques Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France (F.Z., J.P.F.).ORCID 0000-0002-2304-6138
Jennifer B GreenDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (J.B.G.).ORCID 0000-0002-9967-5352
Julio RosenstockDallas Diabetes Research Center at Medical City, TX (J.R.).
Sven SchnaidtBoehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S.).
Martina BrueckmannBoehringer Ingelheim International GmbH, Ingelheim, Germany (M.B.).ORCID 0000-0003-1215-0746
Stuart J PocockDepartment of Medical Statistics, London School of Hygiene & Tropical Medicine, UK (S.J.P.).
Milton PackerBaylor University Medical Center, Dallas, TX (M.P.).ORCID 0000-0003-1828-2387
Stefan D AnkerDepartment of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany (S.D.A.).ORCID 0000-0002-0805-8683
EMPEROR-Preserved Trial Committees and Investigators
Inserm · FRBaylor University Medical Center · USBoehringer Ingelheim (Germany) · DEDallas Diabetes Research Center · USDiabetes Australia · AUDuke University · USGerman Centre for Cardiovascular Research · DENational and Kapodistrian University of Athens · GRUniversity of London · GBUniversity of Mannheim · DEUniversity of Mississippi · USUniversity of Nicosia · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmpagliflozin improves outcomes in patients with heart failure with a preserved ejection fraction, but whether the effects are consistent in patients with and without diabetes remains to be elucidated.

methodsPatients with class II through IV heart failure and a left ventricular ejection fraction >40% were randomized to receive empagliflozin 10 mg or placebo in addition to usual therapy. We undertook a prespecified analysis comparing the effects of empagliflozin versus placebo in patients with and without diabetes.

resultsOf the 5988 patients enrolled, 2938 (49%) had diabetes. The risk of the primary outcome (first hospitalization for heart failure or cardiovascular death), total hospitalizations for heart failure, and estimated glomerular filtration rate decline was higher in patients with diabetes. Empagliflozin reduced the rate of the primary outcome irrespective of diabetes status (hazard ratio, 0.79 [95% CI, 0.67, 0.94] for patients with diabetes versus hazard ratio, 0.78 [95% CI, 0.64, 0.95] in patients without diabetes;

conclusionsIn patients with heart failure and a preserved ejection fraction enrolled in the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction), empagliflozin significantly reduced the risk of heart failure outcomes irrespective of diabetes status at baseline. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03057951.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosidesHumansStroke VolumeVentricular Function, LeftBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsdeathdiabetes mellitusheart failurehospitalizationprognosis

Identifiers

PMID35762322
PMCPMC9422757
OpenAlexW4283709876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.